Bovine tuberculosis remains a major economic and animal welfare concern worldwide. Cattle vaccination is being considered as part of control strategies. This approach, used alongside conventional control policies, also requires the development of vaccine-compatible diagnostic assays to distinguish vaccinated from infected animals (DIVA). We discuss progress made on optimizing the only potentially available vaccine, bacille Calmette Guérin (BCG), and on strategies to improve BCG efficacy. We also describe recent advances in DIVA development based on the detection of host cellular immune responses by blood-testing or skin-testing approaches. Finally, to accelerate vaccine development, definition of host biomarkers that provide meaningful stage-gating criteria to select vaccine candidates for further testing is highly desirable. Some progress has also been made in this area of research, and we summarize studies that defined either markers predicting vaccine success or markers that correlate with disease stage or severity.
History
Rights statement
This paper was authored by employees of the British Government as part of their official duties and is therefore subject to Crown Copyright. Reproduced with the permission of the Controller of Her Majesty's Stationery Office/Queen's Printer for Scotland and the Animal Plant and Health Agency.
Language
English
Does this contain Māori information or data?
No
Publisher
Annal Reviews
Journal title
Annual Review Animal Bioscience
ISSN
2165-8102
Citation
Vordermeier, H. M., Jones, G. J., Buddle, B. M., Hewinson, R. G., & Villarreal-Ramos, B. (2016). Bovine tuberculosis in cattle: vaccines, DIVA tests, and Host Biomarker Discovery. Annual Review of Animal Biosciences, 4, 87-109. DOI: 10.1146/annurev-animal-021815-111311